SARS-CoV-2 Neutralizing Antibody ELISA Kit (HUES0362)
Anti-SARS-CoV-2 Neutralization Antibody Test Kit
What are SARS-CoV-2 neutralizing antibodies and why is this kit important?
SARS-CoV-2 neutralizing antibodies give essential information for determining the immune response to COVID-19. Detection of these is important for understanding immunity and vaccine development.
It has recently been shown that SARS-CoV-2 infection elicits robust neutralizing antibody titers in most individuals that last beyond 6 months. In addition, Neutralizing antibodies are a key correlate of protection against SARS-CoV-2 infection so measurement of these is a key determinant of immunity towards COVID-19 (Lau, E.H.Y., Tsang, O.T.Y., Hui, D.S.C. et al. Neutralizing antibody titres in SARS-CoV-2 infections. Nat Commun 12, 63 (2021).
Finally & most importantly, COVID-19 vaccines have been shown to elicit strong SARS-CoV-2 neutralizing antibody responses hence the detection of these is one of the key determinants in understanding the efficacy of COVID-19 vaccines (Worzner et al., 63, 103197, Ebiomedicine, 2021. Adjuvanted SARS-CoV-2 spike protein elicits neutralizing antibodies and CD4 T cell responses after a single immunization in mice).
Key features of the Assay Genie SARS-CoV-2 Neutralizing Antibody ELISA Kit:
- Qualitative detection assay for neutralizing antibodies against SARS-CoV-2 (COVID-19)
- Use with human serum or plasma samples
- Rapid 1h30m protocol
The Assay Genie SARS-CoV-2 Neutralizing Antibody ELISA kit is a qualitative detection assay for neutralizing antibodies against SARS-CoV-2 (COVID-19) in human serum or plasma. Neutralizing antibodies can be produced in high titres by various COVID-19 vaccines. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2, previously designated 2019-nCoV) is the pathogen of coronavirus disease 2019 (COVID-19), which is a positive-sense single-stranded RNA virus that belongs to the family of coronaviruses. The most common symptoms of COVID-19 are fever, coughing, and breathing difficulties. The incubation period of COVID-19 commonly ranges from 2 to 14 days, with an average of 5 days although there also have few cases with 24 days incubation periods. Normally, the time from infection onset to onset of symptoms is one week. Coronaviruses encode four major structural proteins, spike (S), membrane (M), envelop (E), nucleocapsid (N) and notably, S protein contains a receptor-binding domain (RBD) which is one of the vital immunodominant epitopes and has a superior capacity to induce Neutralization antibodies. The RBD of SARS-CoV-2 is responsible for recognizing and interacting with the cell surface receptor, angiotensin-converting enzyme-2 (ACE2). In the respiratory tract, ACE2 is widely expressed on the cell surface of alveoli, trachea, bronchi, macrophages, etc. Following the binding of the RBD to the receptor ACE2, SARS-CoV-2 enters target cells, where the fusion of the virus envelops the endosome membranes and leads to the release of the viral nucleocapsid into the cytosol of the infected cell.
This is a qualitative competitive ELISA kit to detect the Anti-SARS-CoV-2 Neutralization Antibodies in human serum or plasma. The micro test plate provided in this kit is pre-coated with recombinant human ACE2. During the reaction, the SARS-CoV-2 neutralization antibody in the sample diluent pre-treated samples or controls competes with a fixed amount of human ACE2 on the solid phase supporter for sites on the Horseradish peroxidase (HRP) conjugated recombinant SARS-CoV-2 RBD fragment (HRP-RBD). After 37℃ incubation, the unbound HRP-RBD as well as any HRP-RBD bound to non-neutralization antibody will be captured on the plate and eventually form the ACE2-RBD-HRP complex, while the circulating neutralization antibodies HRP-RBD complexes remain in the supernatant and are removed during washing. Then a TMB substrate solution is added to each well. The enzyme-substrate reaction is terminated by the addition of stop solution and the color change is measured spectrophotometrically at a wavelength of 450 nm ± 2 nm. Compared with the inhibition ratio to judge whether SARS-CoV-2 Neutralization Antibody exists in the tested samples or not.
|Micro test plate||8 wells×12 strips||2 plates, 96T||5 plates, 96T||10 plates, 96T|
|Positive control||1 vial||2 vials||5 vials||10 vials|
|Negative control||1 vial||2 vials||5 vials||10 vials|
|Sample diluent||1 vial, 20 mL||2 vials, 20 mL||5 vials, 20 mL||10 vials, 20 mL|
|Concentrated HRP conjugated RBD(HRPRBD, 100×)||1 vial, 120 μL||2 vials, 120 μL||5 vials, 120 μL||10 vials, 120 μL|
|HRP conjugate diluent||1 vial, 10 mL||2 vials, 10 mL||5 vials, 10 mL||10 vials, 10 mL|
|Concentrated wash buffer(25×)||1 vial, 30 mL||2 vials, 30 mL||5 vials, 30 mL||10 vials, 30 mL|
|TMB substrate solution||1 vial, 10 mL||2 vials, 10 mL||5 vials, 10 mL||10 vials, 10 mL|
|Stop solution||1 vial, 10 mL||2 vials, 10 mL||5 vials, 10 mL||10 vials, 10 mL|
|Plate sealer||3 pieces||6 pieces||15 pieces||30 pieces|
|Product description||1 copy||1 copy||1 copy||1 copy|
Note: All reagent bottle caps must be tightened to prevent evaporation and microbial contamination. The volume of reagents in partial shipments is a little more than the volume marked on the label, please use accurate measuring equipment when making working solutions.
Other material needed but not supplied
- Microplate reader with 450 nm wavelength filter
- High-precision transfer pettor, EP tubes and disposable pipette tips
- Incubator capable of maintaining 37℃
- Deionized or distilled water
- Absorbent paper
- Loading slot for wash buffer
- Automatic microplate washer (recommended, the washing step can also be carried out manually)
- Paper towel
- Disinfecting agent
Storage and stability
- The test kit has to be stored at 2-8℃ , do not freeze and avoid exposure to direct sunlight. The unopened is stable for at least 6 months
- The opened kit can be stored at 2-8℃ for 2 weeks
- All reagents must be brought to room temperature (18-25℃ ) at least 30 min before use. If the kit will not be used up in one assay, please only take out the necessary strips and reagents for present experiment, and store the remaining strips and reagents at required condition.
- Wash buffer: Dilute 30mL of concentrated wash buffer with 720mL of deionized or distilled water to prepare 750mL of wash buffer. Note: if crystals have formed in the concentrate, warm it in a 40℃ water bath and mix it gently until the crystals have completely dissolved.
- HRP conjugated RBD: Calculate the required amount before the experiment (50μL/well). In preparation, slightly more than calculated should be prepared. Dilute the 100× concentrated HRP-RBD to 1× working solution with HRP conjugate diluent. Note: The HRP-RBD working solution should be stored at 2-8℃ and used within 1 days.
- Samples: Dilute samples with sample diluent with a volume ratio of 1:9.
- Positive control：Dissolve positive control with 0.3mL sample diluent.
- Negative control：Dissolve negative control with 0.5 mL sample diluent.
Sample collection and preparation
Serum: Allow samples to clot for 1 hour at room temperature or overnight at 2-8℃ before centrifugation for 20 min at 1000×g at 2-8℃ . Collect the supernatant to carry out the assay. The suspended fibrous protein may cause a false positive result if not fully precipitated. Obviously contaminated samples can't be detected.
Plasma: Collect plasma using EDTA or heparin sodium as an anticoagulant. Centrifuge samples for 15 min at 1000×g at 2- 8℃ within 30 min of collection. Collect the supernatant to carry out the assay. Before assaying, prepare the samples as per the following instructions: Sample dilution: Dilute the serum or plasma with sample diluent with a volume ratio of 1:9, mix thoroughly.
- Handle all serum and plasma as if capable of transmitting infectious agents.
- Tubes for blood collection should be disposable and be non-endotoxin. Severe hemolysis, lipoid, or turbidity samples should not be used.
- Samples should be assayed stored at 2-8℃ within 3 days. Avoid repeated freeze-thaw cycles or overheated. Prior to assay, the frozen samples should be slowly thawed and centrifuged to remove precipitates. Frozen samples must be mixed well and brought to room temperature before testing.
Pos.: positive control;
Neg.: negative control;
- Determine wells for positive and negative controls and samples. Add 50μL each pre-treated samples and controls into the appropriate wells (It is recommended that all samples and controls be assayed in duplicate). Immediately add 50μL of HRP conjugated SARS-CoV-2 RBD fragment (HRP-RBD) working solution to each well. Cover the plate with the sealer provided in the kit. Incubate for 60 min at 37℃. Note: solutions should be added to the bottom of the micro test plate well, avoid touching the inside wall or creating foam during pipetting.
- Decant the solution from each well and add 350μL of wash buffer. Soak for 30-60 seconds and aspirate or decant the solution from each well. Pat dry against clean absorbent paper. Repeat this wash step 3 times. Note: a microplate washer can be used in this step and other wash steps. Make the tested strips in use immediately after the wash step. Do not let the wells dry out.
- Add 90μL of substrate reagent to each well. Cover the plate with a new sealer. Incubate for about 15 min at 37℃ . Protect the plate from light. Note: the reaction time can be shortened or extended according to the actual color change, but not more than 30min. Preheat the microplate reader for about 15 min before OD measurement.
- Add 50μL of stop solution to each well. Note: adding the stop solution should be done in the same order as the substrate solution.
- Determine the optical density (OD value) of each well at once with a micro-plate reader set to 450 nm.
|Add 50μL of pre-treated samples and controls into the appropriate wells|
|Immediately add 50μL of HRP conjugated SARS-CoV-2 RBD fragment |
(HRP-RBD) working solution to each well
|Wash with 350 μL of diluted wash buffer per well for 3 times|
|Add 90μL of TMB substrate reagent to each well|
|37°C 15 min|
|Add 50μL of stop solution to each well|
|Read immediately at 450 nm|
For each assay, both Positive and Negative Controls must be included to validate the results. The OD450 of each Control must meet the requirements as follows, otherwise, the test is invalid and should be repeated.
OD of Negative Control＞1.2
OD of Positive Control＜0.4
The OD of the negative control is used to calculate the inhibition, and the OD of positive control is only used to evaluate the validity of the results. The inhibition of each sample can be calculated with the formulation as follows:
Inhibition = (1- (OD value of sample / OD value of Negative Control)) x 100
Inhibition ≥ 20%: Positive, Neutralization antibodies for SARS-CoV-2 are detected.
Inhibition ＜ 20%: Negative, Neutralization antibodies for SARS-CoV-2 are not detected
- This kit is intended for the semi quantitative detection of neutralization antibodies against SARS-CoV-2 in human serum or plasma.
- For Research-Use-Only.
- Negative results do not rule out SARS-CoV-2 infection, particularly those who have been in contact with the virus recently. Positive results may be due to current or past infection with non-SARS-CoV-2 corona virus strains. Results from this kit should not be used to diagnose or to exclude acute SARS-CoV-2 infection or to inform infection status.
- For the suspicious samples near borderline. It is recommended to re-determine and supervise dynamically.
- Due to methodological or immuno-specific reasons, the same sample may yield different results by using reagents from different manufacturers. Therefore, the test results of different kits should not be directly compared with each other to avoid erroneous medical interpretations. It is recommended that the laboratory shall indicate the source of the reagents used in the test report. And in continuous monitoring, additional continuity testing should be performed and parallel comparison with the original reagent results to re-determine the baseline value if the reagent type is changed.
- Results from immunosuppressed patients should be interpreted with caution.
- Avoid using cross-contamination, microbial contamination, severe hemolysis, or turbid samples.
- Repeatability: CV ≤ 15%
- Analysis specificity: There is no cross-reaction with antibody/antigen positive sera samples from patients with other human coronaviruses (HCoV-HKU1, HCoVOC43, HCoV-NL63, HCoV-229E), or non-coronaviruses, including influenza A virus (H1N1, H3N2, H5N1, H7N9), influenza B virus (yamagata lineages, victoria lineages), respiratory syncytial virus, rhinovirus, adenovirus, enterovirus, epstein-barr virus, measles virus, human cytomegalovirus, rotavirus, norovirus, mumps virus, herpes zoster virus, or mycoplasma pneumoniae.
- When determining the cut-off value of this kit, 500 serum samples of healthy people have been measured, take the 95% upper limit as cut-off value. The cut-off value : ＜ 20%
- For Research-Use-Only
- Read the instruction manual carefully before operation, and perform the test operation strictly following the instruction.
- Do not eat, drink or smoke in the area where samples or kits are handled. Avoid testing in harsh environments (such as environments containing sodium hypochlorite, acid-base or acetaldehyde, and other high concentration corrosive gases and dust). Disinfection should be performed after the test.
- Wear lab coats, eye protection and disposable gloves while handling the kit reagents and wash hands thoroughly.
- Human source material used to prepare the controls included in this kit should be handled as potentially infectious material. Use universal precautions when handling.
- The kit should not be used beyond the expiration date on the kit label.
- Do not mix components from different batches. Do not mix with components from other manufacturers.
- Do not reuse the used kit.
- The remaining strips should be sealed in an foil pouch to prevent moisture after the microplate package is opened.
- Change pipette tips in between adding of each control and sample. Also, use separate reservoirs for each reagent.
- Wash the wells gently when adding wash buffer to avoid the contamination between adjacent wells.
- Residual liquid (>10 μL) in the reagent wells after washing can interfere with the substrate and lead to false low OD readings.
- Test incubator must be set to 37± 1℃
- Follow the Instructions of the microplate reader for set-up and preheat it for 15 min before OD measurement.
- Handle all samples cautiously as if they contain infectious agents. Observe established precautions against microbiological hazards throughout the procedure and follow the standard procedures for proper disposal of samples.
- The used reagents, samples and potentially contaminated should be discarded according to the local regulation.